baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Soc. Generale Discount Zert ATO 2.../ DE000SW1AKH3 /

2024-05-15 9:23:45 AM	Chg.+0.01	Bid8:00:00 PM	Ask8:00:00 PM	Underlying	Strike price	Expiration date	Option type
2.03EUR	+0.50%	- Bid Size: -	- Ask Size: -	Atos SE	- EUR	2024-06-28	Call

GlobeNewswire 2:30 PM Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...

GlobeNewswire 12:17 AM Calian Reports Record Results for the Second Quarter

GlobeNewswire 05-13 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 05-13 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing

GlobeNewswire 05-07 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

GlobeNewswire 04-29 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 04-15 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...

GlobeNewswire 04-11 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

GlobeNewswire 04-09 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...

GlobeNewswire 04-01 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire 03-27 Calian Announces the Appointment of New President of Advanced Technologies

GlobeNewswire 03-25 Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks

GlobeNewswire 03-19 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...

GlobeNewswire 03-18 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

GlobeNewswire 03-12 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...

GlobeNewswire 03-06 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...

GlobeNewswire 02-22 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

GlobeNewswire 01-16 New report reveals that 94% of global organizations have experienced email security incidents last y...

GlobeNewswire 01-09 Atossa Therapeutics Issues Letter to Shareholders

TeleTrader 01-03 Europe opens mixed with data, business in focus

TeleTrader 01-03 Airbus to purchase Atos' cyber security unit for $1.9B

GlobeNewswire 2023-12-13 Sodexo announces the composition of Pluxee’s future Board of Directors

GlobeNewswire 2023-12-04 Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

GlobeNewswire 2023-11-20 Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

GlobeNewswire 2023-11-13 Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Soc. Generale Discount Zert ATO 2.../ DE000SW1AKH3 /

If you wish to receive reply to your feedback, please provide your email address.